Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    DMXE molecular structure

    DMXE Stats & Data

    3d-mxe Warm-k 3-me-2'-oxo-pce
    NPS DataHub
    MW231.34
    FormulaC15H21NO
    IUPAC2-(ethylamino)-2-(3-methylphenyl)cyclohexan-1-one
    SMILESCCNC1(CCCCC1=O)c1cccc(C)c1
    InChIKeyWIMLPRYZJQNQLE-UHFFFAOYSA-N
    Arylcyclohexylamines
    Chemical Class Arylcyclohexylamine
    Psychoactive Class Dissociative

    Receptor Profile

    Receptor Actions

    Antagonists
    NMDA receptor antagonist (noncompetitive)

    History & Culture

    DMXE emerged as a novel research chemical around October 2020, when it first appeared on online designer drug markets. The compound is structurally derived from methoxetamine (MXE), with the 3-methoxy substituent replaced by a methyl group—hence its alternative designation as "3D-MXE" (3-desmethoxy-MXE). It was first definitively identified by a forensic laboratory in Denmark in February 2021, marking its formal entry into scientific documentation of novel psychoactive substances. The compound appeared during a period of continued innovation in the arylcyclohexylamine research chemical space, following patterns established by earlier designer dissociatives. Its emergence reflects ongoing efforts within clandestine chemistry to develop structural analogues of controlled or unavailable substances like MXE.

    Effect Profile

    Curated + 9 Reports
    Dissociative 5.7

    Strong dissociative depth with strong motor impairment, moderate mania, low insight

    Dissociative Depth×3
    10
    Mania / Compulsion×1
    6
    Insight / Novel Thought×2
    3
    Motor / Sensory Impairment×1
    10

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Insufflated
    4-15 minutes
    15-30 minutes
    30 minutes - 1.5 hours
    2-3 hours
    1-2 hours
    Oral
    19-40 minutes
    30 minutes - 1.0 hours
    30 minutes - 1.5 hours
    2-3 hours
    1-2 hours

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans; user reports suggest a duration on the order of hours (commonly 4–7 h total depending on ROA), but no validated PK data are available; treat estimates such as 3–6 h as speculative.
    Addiction Potential
    Moderate psychological dependence risk similar to other arylcyclohexylamine dissociatives; binge-style redosing and frequent use increase risk.

    Tolerance Decay

    Full tolerance 1d Half tolerance 14d Baseline ~28d

    Acute tolerance rises within a session and across days; many users report unpredictability and diminished effects with frequent use. Long washouts (≥4 weeks) are commonly used to restore baseline response. Estimates are anecdotal and inferred from MXE/ketamine patterns and community reports on DMXE.

    Cross-Tolerances

    ketamine
    methoxetamine (MXE)
    MXPr
    other arylcyclohexylamines

    Experience Report Analysis

    Erowid
    14 Reports
    9 Single-substance
    2020–2024 Date Range
    14 With Age Data
    17 Effects Detected

    Demographics

    Gender Distribution

    Too few reports for a chart: gender is known from 14 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

    • Male 10 of 14
    • Not Specified 3 of 14
    • Female 1 of 14

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 9 experience reports (9 single-substance Erowid)

    9 Reports
    17 Effects Detected
    6 Positive
    5 Adverse
    6 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

    Too few reports for bars: these effects come from 9 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    Positive Effects 6

    Music Enhancement 7 of 9 70%
    Color Enhancement 6 of 9 70%
    Stimulation 6 of 9 70%
    Empathy 6 of 9 70%
    Body High 5 of 9 70%
    Introspection 4 of 9 70%

    Adverse Effects 5

    Anxiety 4 of 9 70%
    Motor Impairment 3 of 9 70%
    Confusion 3 of 9 70%
    Memory Suppression 3 of 9 70%
    Nausea 3 of 9 70%
    Show 6 neutral or unclassified mentions
    Visual Distortions 8 of 9
    Dissociation 5 of 9
    Closed-Eye Visuals 4 of 9
    Auditory Effects 4 of 9
    Sedation 3 of 9
    Ego Dissolution 3 of 9

    Real-World Dose Distribution

    Erowid

    From 11 of 12 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

    Insufflated (n=11)

    Median: 55.0mg 25th: 22.5mg 75th: 65.0mg 90th: 70.0mg

    Form / Preparation

    Most common forms and preparations, as a share of the 9 reports that give one

    Too few reports for bars: these forms come from 9 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    • Powder / Crystals 4 of 9
    • Liquid 4 of 9

    Harm Reduction

    drugs.wiki

    • Identity: DMXE = 3-Me-2′-oxo-PCE, also known as 3D‑MXE. This places it in the ketamine/PCx family with likely NMDA receptor antagonism; human pharmacokinetics remain poorly characterized. • Mislabeling risk: Drug checking services have found DMXE sold as MXE; do not assume a vendor or pellet label is accurate—use reagent/lab testing where available. • Combining CNS depressants (alcohol, GHB/GBL, opioids) with dissociatives markedly increases risks of loss of consciousness, aspiration and respiratory depression; if someone becomes unresponsive, place them in the recovery position and seek help. • Benzodiazepines and dissociatives potentiate each other’s sedation/ataxia and can lead to unexpected blackouts at high doses; treat as a caution-only combination. • Stimulant or serotonergic co-use (e.g., MDMA/SSRIs) can produce unpredictable effects (e.g., anxiety, blood-pressure elevation, or unusual mood shifts), and MXE analogs have specific MAOI/SSRI cautions—avoid such mixes or proceed only with expert-level caution. • Repeated/frequent dissociative use is linked to urinary tract (‘ketamine cystitis’) and biliary complications with ketamine; similar risks may generalize to analogs—watch for urinary urgency, pain or blood; take prolonged breaks and stop use if symptoms appear. • Expect marked motor impairment and poor situational awareness—clear hazards, stay seated/lying at higher doses, and never drive. General dissociative harm-reduction stresses environment control and moderation. • Intranasal use: crush finely; avoid shared/contaminated implements; rinse with sterile saline before/after to reduce mucosal damage. • Potency and duration vary by batch and route; some users report prolonged residual dissociation after high cumulative dosing or all‑night redosing—resist the urge to ‘chase the hole’ and allow full plateaus to resolve before considering more. • The smell or color of product (e.g., tan/odorous powder, black/grey pellets) is not a quality guarantee and may reflect impurities or excipients; lab testing beats home ‘purification’ hacks.

    ← Back to DMXE